We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Amneal Pharmaceuticals (AMRX) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Amneal Pharmaceuticals (AMRX - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Amneal Pharmaceuticals is one of 984 companies in the Medical group. The Medical group currently sits at #7 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Amneal Pharmaceuticals is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for AMRX's full-year earnings has moved 4.4% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that AMRX has returned about 1.8% since the start of the calendar year. At the same time, Medical stocks have lost an average of 2.5%. This means that Amneal Pharmaceuticals is performing better than its sector in terms of year-to-date returns.
Another Medical stock, which has outperformed the sector so far this year, is Boston Scientific (BSX - Free Report) . The stock has returned 18.8% year-to-date.
In Boston Scientific's case, the consensus EPS estimate for the current year increased 2.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Amneal Pharmaceuticals belongs to the Medical - Drugs industry, a group that includes 155 individual companies and currently sits at #78 in the Zacks Industry Rank. This group has gained an average of 6.8% so far this year, so AMRX is slightly underperforming its industry in this area.
In contrast, Boston Scientific falls under the Medical - Products industry. Currently, this industry has 84 stocks and is ranked #173. Since the beginning of the year, the industry has moved +6.7%.
Amneal Pharmaceuticals and Boston Scientific could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Amneal Pharmaceuticals (AMRX) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Amneal Pharmaceuticals (AMRX - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Amneal Pharmaceuticals is one of 984 companies in the Medical group. The Medical group currently sits at #7 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Amneal Pharmaceuticals is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for AMRX's full-year earnings has moved 4.4% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that AMRX has returned about 1.8% since the start of the calendar year. At the same time, Medical stocks have lost an average of 2.5%. This means that Amneal Pharmaceuticals is performing better than its sector in terms of year-to-date returns.
Another Medical stock, which has outperformed the sector so far this year, is Boston Scientific (BSX - Free Report) . The stock has returned 18.8% year-to-date.
In Boston Scientific's case, the consensus EPS estimate for the current year increased 2.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Amneal Pharmaceuticals belongs to the Medical - Drugs industry, a group that includes 155 individual companies and currently sits at #78 in the Zacks Industry Rank. This group has gained an average of 6.8% so far this year, so AMRX is slightly underperforming its industry in this area.
In contrast, Boston Scientific falls under the Medical - Products industry. Currently, this industry has 84 stocks and is ranked #173. Since the beginning of the year, the industry has moved +6.7%.
Amneal Pharmaceuticals and Boston Scientific could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.